Gameto
Overview
Gameto is a biotechnology company specializing in women’s health solutions, primarily focusing on reproductive longevity and fertility treatments. Founded in 2020 by Dina Radenkovic, Pranam Chatterjee, and Martin Varsavsky, Gameto is headquartered in New York City. The company has raised a total of $83 million through various funding rounds. Gameto employs around 33 people who are dedicated to advancing women’s health by developing cellular therapies and innovative hormone-free fertility treatments.
Recent Developments
- October 2024: Gameto was awarded a $10 million grant from the Advanced Research Projects Agency for Health (ARPA-H) as part of their Sprint for Women’s Health initiative. This funding is allocated to support the development of therapeutic solutions addressing menopause.
- July 2024: At the European Society of Human Reproduction and Embryology Annual Meeting, Gameto presented advances in their in vitro maturation technology, Fertilo, which involves maturing eggs outside the body using ovarian support cells.
- May 24, 2024: Gameto completed a $33 million Series B funding round led by Two Sigma Ventures and RA Capital Management. The funds will further the clinical development of Fertilo, enhancing accessibility and efficacy in fertility treatments.
- April 2024: Gameto announced advancements in their secondary program, Deovo, focusing on ovarian aging and computational biology.
- January 2024: Gameto revealed their strategic partnership with designer Stacey Bendet to launch the "Your Eggsperience Matters" campaign during National Infertility Awareness Week to raise funds for RESOLVE, a national infertility association.
- December 2023: Gameto announced FDA’s tentative approval to proceed with Phase 3 trials for Fertilo, subject to completion of certain studies and regulatory requirements.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2020 |
| Headquarters | New York, NY, USA |
| Founders | Dina Radenkovic, Pranam Chatterjee, Martin Varsavsky |
| Revenue | - |
| Profits | - |
| Key Investors | Two Sigma Ventures, RA Capital, Insight Partners |
| Industry | Biotechnology |
| Number of Employees | 33 |
Early History
Gameto was founded in 2020 with the mission of addressing accelerated ovarian aging, a key challenge in women’s reproductive health. Drawing inspiration from earlier research conducted at the Church Lab at Harvard Medical School, the founders sought to leverage cellular engineering to tackle infertility and menopause related issues. The company quickly garnered attention from investors, securing $3 million in seed funding by March 2020, which laid the groundwork for developing their flagship product, Fertilo.
Company Profile and Achievements
Gameto operates at the intersection of biotechnology and women’s health, seeking to redefine fertility treatment protocols with less invasive, hormone-free solutions. Key achievements include:
- Development of Fertilo: A pioneering in vitro maturation solution aimed at reducing the hormonal burden of traditional IVF and egg freezing.
- Expansion Plans: Following successful trials, the company plans to roll out Fertilo commercially across Australia and Latin America by 2025.
- Collaborative Initiatives: Gameto has actively engaged in strategic partnerships, including collaborations with fertility clinics and participation in international conferences to promote their research and solutions.
- Awards and Recognition: The company’s innovative approach has led to Gameto being recognized as a Technology Pioneer by the World Economic Forum.
Current Operations and Market Position
Gameto is currently operating as a privately held biotechnology firm. With a strong focus on research and development, the company maintains a promising pipeline of products aimed at extending reproductive healthspan. Gameto fortifies its market position with robust partnerships and clinical trials aimed at validating and refining Fertilo. This, coupled with strategic funding and approvals from regulatory bodies, positions Gameto as a significant player in the competitive landscape of women’s health biotechnology.
Conclusion
Gameto has established itself as a transformative force within the biotechnology industry, particularly in the realm of reproductive health. Their forward-thinking approach to women’s health, employing cellular engineering to reimagine fertility treatments, positions them at the forefront of addressing complex medical challenges. As they continue garnering support from both financial and scientific communities, Gameto is expected to play a pivotal role in shaping the future of fertility and women’s health treatments.